Prodromal Initiative to Identify Biomarkers for Parkinson’s
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
586 RESULTS
Sort By:
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
Do blood components really leak across an inflamed blood-brain barrier early on in the development of Alzheimer’s disease? Some GWAS hits and budding neuro-imaging and fluid markers are helping researchers find out.
A small longitudinal study suggests that atrophy begins in the frontoparietal cortex, not the hippocampus, in early Alzheimer's.
European and U.S. agencies approve a third amyloid PET tracer, florbetaben.
Will an antibody signature make for a new Alzheimer’s diagnostic?
A candidate reference method for measuring Aβ42 in cerebrospinal fluid brings researchers closer to standardization.
Big-data project takes on Alzheimer's with a biomarker computational challenge.
Brain-training websites tout their games’ potential to boost cognition, but strong evidence and firm backing by the scientific community have yet to surface.
While scientists remain on the fence over whether computer games benefit cognition, some are finding new uses for gaming data in clinical trial research.
In a large retrospective study, people with the highest plasma levels of an inflammatory protein experienced the greatest decline in reasoning abilities over the next 10 years.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Researchers continue to screen blood for factors that signal neurodegenerative disease.
Connections across neural networks break down as cognition declines in people with different forms of AD, suggesting the wiring problems may be a hallmark of disease progression.
Compounds that bind RNA temper toxicity related to ALS and FTD.
When strict quality control standards are followed, low Aβ in cerebrospinal fluid accurately predicts amyloid plaques in people with cognitive impairment in clinical practice.